What are the side effects of Relugolix?

Relugolix is an oral small-molecule gonadotropin-releasing hormone (GnRH) antagonist that can effectively block androgen production and is used to treat advanced prostate cancer. Repagolic is a prescription drug used to treat advanced prostate cancer in adult men. Repagolictablets work by reducing the amount of testosterone your body produces, which may slow or stop the spread of prostate cancer cells that need testosterone to grow.

The most common adverse reactions (≥ 10%) and laboratory abnormalities (≥ 15%) were hot flashes, elevated blood sugar, elevated triglycerides, musculoskeletal pain, reduced hemoglobin, elevated alanine aminotransferase (ALT), fatigue, elevated aspartate aminotransferase (AST), constipation and diarrhea.

The protein binding rate of Repagliflozin in plasma is 68-71%, and it is mainly bound to albumin and secondarily to α1-acidic glycoprotein. Repaglifloxis mainly metabolized by the CYP3A subfamily of P450 enzymes, CYP2C8 plays a smaller role. Approximately 81% of the oral dose was recovered in feces, of which 4.2% was unchanged parent drug, and 4.1% of the dose was recovered in urine, of which 2.2% remained unchanged. Repagliflozin has a mean effective half-life of 25 hours, and a mean terminal elimination half-life of 60.8 hours. Repagolic has a mean renal clearance of 8 L/h and a total clearance of 26.4 L/h. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.